A statement released earlier today by Panmure Gordon about Abcam PLC (LON:ABC) bumps the target price to 640.00GBX
- Updated: September 25, 2016
Stating as potential downside of -0.24%, Panmure Gordon upped the price target of Abcam PLC (LON:ABC) to 640.00GBX
On Wednesday September 14, 2016, JP Morgan Cazenove released a statement on Abcam PLC (LON:ABC) dropped the target price from 781.00GBX to 678.00GBX that suggested an upside of 0%.
Having a price of 838.25GBX, Abcam PLC (LON:ABC) traded -0.54% lower on the day. With the last close up 23.24% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Abcam PLC has recorded a 50-day average of 760.80GBX and a two hundred day average of 678.35GBX. Volume of trade was down over the average, with 21,099 shares of ABC changing hands under the typical 651,993
With a total market value of 0 GBX, Abcam PLC has price-earnings ratio of 45.19 with a one year low of 547.00GBX and a one year high of 842.00GBX .
More About Abcam PLC (LON:ABC)
Abcam plc is engaged in producing and marketing protein research tools. The Company offers products, such as primary antibodies, including monoclonals, polyclonals, conjugated primary antibodies, tags and cell markers, loading controls, flow cytometry antibodies and others; secondary antibodies, such as Alexa Fluor conjugated secondaries, alkaline phosphatase (AP), horseradish peroxidase (HRP), Biotin and others; immunoassay kits and reagents, such as lateral flow and dipstick assays, antibody arrays and others; cell and tissue imaging tools, such as fluorescent cell imaging and immunohistochemistry (IHC); cellular and biochemical assays, such as cell signaling, and cell damage and oxidative stress, and others; proteins and peptides, such as enzymes, signaling proteins and others; proteomics tools, cellular fractionation and others; lysates, such as cytoplasmic, membrane and others; multiplex micro ribonucleic acid (miRNA) assays, and agonists, activators, antagonists and inhibitors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.